West Lafayette, IN – According to filings with the U.S. Securities and Exchange Commission, MorphImmune is raising $19,000,001.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Ronald Martell played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About MorphImmune
MorphImmune, Inc. is a private platform company that is advancing a highly specific targeting technology that uses a ligand-linked payload to reprogram the immune system. The MorphImmune Chemistry Platform enables physicians to drug previously undruggable physiological pathways in treating an array of cancers, chronic diseases and other conditions mediated by the immune system. We design targeted drugs to reprogram specific immune cell types (macrophages, T cells, antigen presenting cells, Fc receptor expressing cells) for treatment of malignant, CNS, infectious, autoimmune and fibrotic diseases and develop ligand-targeted chemotherapies, radiotherapies, and immunotherapies of cancer.

To learn more about MorphImmune, visit http://www.morphimmune.com/

Contact:
Ronald Martell, President and Chief Executive Officer
650-238-4942
ronald.martell@morphimmune.com
https://www.linkedin.com/in/ronald-martell-60b5788/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved